



June 2, 2022

Dear Investor,

We are excited to share with you an update on the progress 3DBio has made over the past several months towards achieving our ultimate goal of becoming the most impactful tissue engineering company in the world. We have reached a pivotal moment in the company's history with the initiation of our Phase 1/2a clinical trial and implantation of the AuriNovo™ living ear construct. We have also significantly advanced our nose, annular repair and intervertebral disc programs, and secured a binding capital commitment to fund our continued progress through the middle of next year.

Our progress over the past several months positions us to leverage the platform into many other areas where synthetic implants and tissue grafts are insufficient to address the unmet medical need. We are increasingly seeing the real-world potential of our technology to improve lives, and our vertical integration and control over all key facets of the platform gives us a unique ability to efficiently modify components to tackle new adjacencies. We firmly believe the best is yet to come.

CLINICAL TRIAL

As noted, 3DBio made history by implanting what we believe to be the first 3D-bioprinted living tissue into a human. This was without question a seminal moment for the company as well as for the history and future of regenerative medicine. It also marked the beginning of the next chapter for 3DBio as we prepare to bring multiple programs to the clinic, in addition to our AuriNovo ear product, upon approval, over the next few years.

3DBio is excited about the clinical trial as we are working with the top ear reconstruction surgeons in the world on a product that could revolutionize the way microtia patients are treated. The Phase 1/2a trial is intended to evaluate the safety and preliminary efficacy of AuriNovo in the treatment of grades II-IV microtia.

BEYOND EAR

While we have been focused on the start of the AuriNovo clinical trial, we have also made significant progress across the rest of our pipeline. We have always viewed AuriNovo as the first of many life-changing programs for the living tissue 3D-bioprinting platform we have developed. Over the next two years we expect to make substantial progress in the following domains:

- 1) *NasaNovo (Nose Program)*: We are actively heading towards submitting an IND to the FDA and conducting planning towards the initiation of a clinical trial upon IND approval.
- 2) *AnnuNovo (Annular Repair Program)*: We are accelerating both small and large animal studies in preparation to submit an IDE to the FDA to initiate a first-in-human clinical trial for this product as well.
- 3) *DiscNovo (Whole Intervertebral Disc Program)*: We are excited by the early data we have seen evaluating multiple stem cell approaches as potential allogeneic cell sources and will be launching a focused study over the next few months to feed into our intervertebral disc program and beyond.



- 4) *Vascularity*: While we already see evidence that our platform can support anatomically appropriate levels of vascular ingrowth, we have begun working on expanding our ability to recruit vascularization deep into printed tissues. This capability will underpin our lumpectomy program and, together with other new capabilities that 3DBio is developing, will enable us to progress towards organs.

FINANCING UPDATE

On Friday, April 22nd, 3DBio received a binding commitment to provide the company with enough capital to fund its operations through at least the middle of next year.

As of the end of April, our cash balance stood at more than \$5M, and we have another \$5M slated to come in over the next 4-6 weeks. This means 3DBio will be in the strongest financial position in our history as we explore the right path for a raising a significant amount of capital that can extend our runway for the next 2-3 years – possibly all the way to reaching our first commercial sales.

We would welcome the opportunity to catch up with each and every one of you who would like to discuss our progress in greater detail in the coming weeks. If you would have interest in a one-on-one meeting, please just let us know.

As always, thank you for your support on this journey, we sincerely appreciate it.

A handwritten signature in black ink, appearing to read "Daniel L. Cohen", with a long horizontal flourish extending to the right.

Daniel L. Cohen, Ph.D.
Chief Executive Officer and Co-Founder

Certain information set forth in this letter may constitute "forward-looking statements" under applicable securities laws. There are a number of factors that could cause actual results or outcomes to differ materially from those addressed in such forward-looking statements. Thus, forward-looking statements are provided only as an opportunity to understand management's beliefs and opinions in respect to the company's future prospects.